Source comparison
TB-500 Mechanism of Action Detailed: Research Dosing and Administration Comparison
The table below summarizes TB-500 dosing protocols across published research models, injury types, and administration routes. These data reflect experimental use in laboratory settings. Not clinical recommendations. Myocardial infarction Rat 6 mg/kg Single dos
This comparison does not assign a generated winner or score.
- The table below summarizes TB-500 dosing protocols across published research models, injury types, and administration routes. These data reflect experimental use in laboratory settings. Not clinical recommendations.
- Myocardial infarction
- Rat
- 6 mg/kg
- Single dose at injury
- Intraperitoneal
- 58% reduction in scar size, improved ejection fraction
- Circulation Research 2007
- Tendon laceration
- Horse
- 7.5 mg total
- Weekly × 6 weeks
- Intralesional
- Increased collagen organization, faster return to function
- Equine Veterinary Journal 2012
- Corneal epithelial defect
- Mouse
- 100 μg/eye
- Daily × 5 days
- Topical
- 47% faster re-epithelialization, reduced inflammation
- Am J Pathology 2005
- Skeletal muscle crush injury
- 10 mg/kg
- Every 3 days × 4 doses
- Subcutaneous
- Restored 82% of baseline strength vs 54% untreated
- Journal of Applied Physiology 2014
- Dermal wound healing
- Rabbit
- 2 mg/kg
- Every other day × 10 days
- Accelerated wound closure, increased tensile strength
- Wound Repair and Regeneration 2010
- Stroke (MCAO model)
- Single dose 24h post-injury
- 40% reduction in infarct volume, improved motor recovery
- Journal of Neuroscience 2012
- Research protocols typically use 5–10 mg/kg body weight in rodent models, translating to approximately 0.8–1.6 mg/kg in larger animals via allometric scaling. Subcutaneous and intraperitoneal routes show similar bioavailability, with plasma half-life ranging from 2–6 hours depending on species. Intralesional injection (direct into injured tissue) produces higher local concentrations but requires precise anatomical targeting.
- The most consistent finding across injury types: TB-500 efficacy peaks when administered within 24–72 hours of injury onset, during the inflammatory and early proliferative phases of wound healing. Delayed administration (7+ days post-injury) still improves outcomes but to a lesser degree, suggesting the peptide's greatest value lies in establishing optimal healing conditions early rather than reversing chronic fibrosis.